FDA Approves Drug Combo for Gastric/GEJ Adenocarcinoma
The US Food and Drug Administration (FDA) approved the monoclonal anti-VEGFR2 antibody ramucirumab (Cyramza) in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Cancer Network - Thu, 06 Nov 2014 11:54

FDA Approves Combo Treatment for Stomach, GE Junction Adenocarcinoma
dailyRx - Wed, 05 Nov 2014 12:48

FDA approves CYRAMZA in combination with paclitaxel for advanced ...
News-Medical.net - Wed, 05 Nov 2014 18:45

Lilly & Co. (LLY) Reports FDA Approval of CYRAMZA Combo as GEJ ...
StreetInsider.com (subscription) - Wed, 05 Nov 2014 11:41

FDA Approves Ramucirumab Plus Paclitaxel for Advanced Gastric Cancer
OncLive - Wed, 05 Nov 2014 12:14

FDA expands approval of ramucirumab for advanced gastric cancer
The Oncology Report - Thu, 06 Nov 2014 12:13

Cyramza Approved for Combo Tx in Advanced GI Cancer
Monthly Prescribing Reference - Wed, 05 Nov 2014 12:03



Lung Cancer Patients With Minimally Invasive Adenocarcinoma Have ...
CHICAGO, IL--(Marketwired - October 30, 2014) - Lung cancer patients with minimally invasive adenocarcinoma (MIA) have similar, positive five-year disease-free survival (DFS) and overall survival (OS) rates as patients with adenocarcinoma in-situ (AIS ...
Marketwired (press release) - Thu, 30 Oct 2014 06:07

Study compares five-year DFS and OS rates for patients with AIS and MIA
News-Medical.net - Fri, 31 Oct 2014 06:18

Discover lung adenocarcinoma therapeutic pipeline market review, H2 2014
Adenocarcinoma of the lung (pulmonary adenocarcinoma) is a common histological form of lung cancer that contains certain distinct malignant tissue architectural, cytological, or molecular features, including gland and/or duct formation and/or ...
WhaTech - Thu, 13 Nov 2014 07:11

Nedd4-1 is an exceptional prognostic biomarker for gastric cardia ...
Gastric cardia adenocarcinoma (GCA) is the most aggressive subtype of gastric carcinoma. New molecular markers and therapeutic targets are needed for diagnosis, prognosis and treatment of GCA. This study is to establish the E3 ubiquitin ligase Nedd4-1 ...
7thSpace Interactive (press release) - Fri, 14 Nov 2014 00:48

Lafayette hospital plans pancreatic cancer study
The Advocate reports (http://bit.ly/11TyhFO ) the study will evaluate the medications Abraxane and Gemcitabine in patients diagnosed with metastatic adenocarcinoma of the pancreas. The hospital says the objective of the research is to gather ...
10TV - Tue, 25 Nov 2014 04:45

FOLFIRI may be viable first-line regimen for advanced gastric, esophagogastric ...
Patients with advanced gastric and esophagogastric junction adenocarcinoma who underwent first-line treatment with fluorouracil, leucovorin and irinotecan demonstrated significantly longer time to treatment failure than those treated with epirubicin ...
Healio - Wed, 29 Oct 2014 01:15

Lafayette General Conducting Survey on Pancreatic Cancer Patients
The study will ultimately evaluate the medications Abraxane and Gemcitabine in patients diagnosed with metastatic adenocarcinoma of the pancreas. Lafayette General participates in clinical trials and studies to help improve patient care and disease ...
KATC Lafayette News - Mon, 24 Nov 2014 09:48

Leonardo Cenci tiene a bada un "rinoceronte" che si chiama adenocarcinoma
Toccante cerimonia all'ospedale S. Maria della Misericordia di Perugia per la donazione, ad opera dell'associazione “ Avanti Tutta”, di un impianto di filodiffusione per i malati oncologici. L'impianto, istallato negli ambulatori di Oncologia Medica ...
Tam Tam - Tue, 25 Nov 2014 02:41


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014